Работы, на которые ссылается эта работа

Работ: 171

Работа: Exploring cellular immunotherapy platforms in multiple myeloma

Gene editing for immune cell therapies
Stefanie R. Bailey, Marcela V. Maus
Обзорная статья2019Цитирований: 2
ABI
Insight into mechanisms associated with cytokine release syndrome and neurotoxicity after CD19 CAR-T cell immunotherapy
Cassie Chou, Cameron J. Turtle
Обзорная статья2019Цитирований: 2
ABI
How to Train Your T Cells: Overcoming Immune Dysfunction in Multiple Myeloma
Adam D. Cohen, Noopur Raje, Jessica Fowler +3
Обзорная статья2019Цитирований: 2
ABI
Potent anti-myeloma efficacy of dendritic cell therapy in combination with pomalidomide and programmed death-ligand 1 blockade in a preclinical model of multiple myeloma
Tan-Huy Chu, Manh-Cuong Vo, Hye-Seong Park +4
Статья2020Цитирований: 2
ABI
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
Jeremy S Abramson, M. Lia Palomba, Leo I. Gordon +19
Статья2020Цитирований: 2
ABI
Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells
Rebekka Duhen, Carmen Ballesteros‐Merino, Alexandra K. Frye +12
Статья2021Цитирований: 2
ABI
Synthetic TILs: Engineered Tumor-Infiltrating Lymphocytes With Improved Therapeutic Potential
Anaïs Jiménez-Reinoso, Daniel Nehme-Álvarez, Carmen Domínguez-Alonso +1
Обзорная статья2021Цитирований: 2
ABI
CAR T-cell therapy in multiple myeloma: more room for improvement
Phaik Ju Teoh, Wee Joo Chng
Обзорная статья2021Цитирований: 2
ABI
Individualized genetic makeup that controls natural killer cell function influences the efficacy of isatuximab immunotherapy in patients with multiple myeloma
Haibo Sun, Thomas G. Martin, John Donald Marra +7
Статья2021Цитирований: 2
ABI
The Cancer-Immunity Cycle in Multiple Myeloma
Mika Casey, Kyohei Nakamura
Обзорная статья2021Цитирований: 2
ABI
Expansion of cytotoxic natural killer cells in multiple myeloma patients using K562 cells expressing OX40 ligand and membrane-bound IL-18 and IL-21
Jaya Lakshmi Thangaraj, Minh‐Trang Thi Phan, SoonHo Kweon +14
Статья2021Цитирований: 2
ABI
NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma
Alejandra Leivas, Antonio Valeri, Laura Córdoba +15
Статья2021Цитирований: 2
ABI
CXCR4 and anti-BCMA CAR co-modified natural killer cells suppress multiple myeloma progression in a xenograft mouse model
Yu Yang Ng, Zhicheng Du, Xi Zhang +2
Статья2021Цитирований: 2
ABI
Autologous NK cells as consolidation therapy following stem cell transplantation in multiple myeloma
Hareth Nahi, Michael Chrobok, Stephan Meinke +20
Статья2022Цитирований: 2
ABI
Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells
Gils Roex, Diana Campillo-Davó, Donovan Flumens +6
Статья2022Цитирований: 2
ABI
Novel IL-15 dendritic cells have a potent immunomodulatory effect in immunotherapy of multiple myeloma
Tan-Huy Chu, Manh-Cuong Vo, Jaya Lakshmi Thangaraj +8
Статья2022Цитирований: 2
ABI
Natural killer cells have a synergistic anti-tumor effect in combination with chemoradiotherapy against head and neck cancer
Eun Kyung Jung, Tan-Huy Chu, Manh-Cuong Vo +10
Статья2022Цитирований: 2
ABI
Preclinical and clinical studies of CAR-NK-cell therapies for malignancies
Hongwen Li, Wenting Song, Zhaoming Li +1
Обзорная статья2022Цитирований: 2
ABI
Expanded natural killer cells potentiate the antimyeloma activity of daratumumab, lenalidomide, and dexamethasone in a myeloma xenograft model
Jaya Lakshmi Thangaraj, Sung‐Hoon Jung, Manh-Cuong Vo +11
Статья2022Цитирований: 2
ABI
FT555: Off-the-Shelf CAR-NK Cell Therapy Co-Targeting GPRC5D and CD38 for the Treatment of Multiple Myeloma
John Reiser, Szeman Ruby Chan, Ketan Mathavan +16
Статья2022Цитирований: 2
ABI
Allogeneic CAR-NK Cell Therapy Targeting Both BCMA and GPRC5D for the Treatment of Multiple Myeloma
Zhuoxiao Cao, Cuiqing Yang, Yifang Wang +9
Статья2022Цитирований: 2
ABI
Anti-BCMA-CAR NK Cells Expressing Soluble TRAIL: Promising Therapeutic Approach for Multiple Myeloma in Combination with Bortezomib and γ-Secretase Inhibitors
Benjamin Motais, Sandra Charvátová, Matouš Hrdinka +2
Статья2022Цитирований: 2
ABI
Research progress of neoantigen-based dendritic cell vaccines in pancreatic cancer
Xin Zhang, Zheng Xu, Xiangpeng Dai +2
Обзорная статья2023Цитирований: 2
ABI
Targeting B Cell Maturation Antigen in Patients with Multiple Myeloma: Current Perspectives
Trilok Shrivastava, Frits van Rhee, Samer Al Hadidi
Обзорная статья2023Цитирований: 2
ABI
Без названия
ДругоеЦитирований: 2
ABI